drugset / Trial / NCT03949673
Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip
Phase 2
Terminated
23 enrolled
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd. · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The objective of this exploratory study is to evaluate the cellular and connective tissue composition of joints from patients with Osteoarthritis (OA) who have been treated with fasinumab, compared with those treated with placebo or Non-steroidal anti-inflammatory drugs (NSAIDs).
Timeline
- Start
- 2019-04-08
- Primary completion
- 2020-08-25
- Completion
- 2020-08-25
Outcome
Outcome not reported
Stopped (Enrollment): “Lack of enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | — | — |
| Subject | Diclofenac | Other / unclassified | — | — |
| Subject | Fasinumab | Monoclonal antibody | — | — |
| Subject | Naproxen | Small molecule | — | — |